OncoMatch/Clinical Trials/NCT07788118
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Is NCT07788118 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies 7×19-THEMIS CAR-T cells for relapsed/refractory large b-cell lymphoma (lbcl).
Treatment: 7×19-THEMIS CAR-T cells — This study is aimed to explored the safety and efficacy of 7×19-THEMIS CAR-T cell therapy for large B-cell lymphoma and to conduct an exploratory comparison of the 3-month objective response rate (ORR) and complete remission rate (CR rate) between the experimental cohort and the historical control cohort (NCT04833504).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
CD19-positive (as determined by immunohistochemistry or flow cytometry; based on the most recent tumor biopsy results).
Demographics
Prior therapy
Must have received: CD20 monoclonal antibody
at least two lines of therapy (which must include a CD20 monoclonal antibody and an anthracycline)
Must have received: anthracycline
at least two lines of therapy (which must include a CD20 monoclonal antibody and an anthracycline)
Lab requirements
Blood counts
absolute neutrophil count in peripheral blood ≥ 1,000/μl; platelet count ≥ 45,000/μl
Kidney function
creatinine < 1.5 mg/dl
Liver function
alt/ast ≤ 2.5 times the upper limit of normal; total bilirubin < 1.5 mg/dl
Cardiac function
ejection fraction ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07788118 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received CD20 monoclonal antibody and anthracycline.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify